(Q28475794)

1

0 references

Gianfranco Tulliano

2

0 references

Theresa W Gyorkos

3

0 references

Wessmark Calderon

4

0 references

Elham Rahme

5

0 references

Brian Ward

6

0 references

Maria Cruz

7

0 references

Alejandro Llanos-Cuentas

8

0 references

Greg Matlashewski

PLoS Neglected Tropical Diseases

9

0 references

language of work or name

English

0 references

publication date

28 July 2009

0 references

published in

0 references

volume

3

0 references

issue

7

0 references

page(s)

e491

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

28 July 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

The increase in risk factors for leishmaniasis worldwide

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Drug resistance in leishmaniasis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Advances in leishmaniasis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Resiquimod and other immune response modifiers as vaccine adjuvants

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

New world cutaneous leishmaniasis in travellers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Clinical and experimental advances in treatment of visceral leishmaniasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Geographic distribution and clinical description of leishmaniasis cases in Peru.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Mucosal leishmaniasis ("espundia" Escomel, 1911).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2710502

Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000491

Development of a genetic assay to distinguish between Leishmania viannia species on the basis of isoenzyme differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000491

Typing of four genetic loci discriminates among closely related species of New World Leishmania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000491

Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000491

Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19636365

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19636365